中华全科医师杂志
中華全科醫師雜誌
중화전과의사잡지
CHINESE JOURNAL OF GENERAL PRACTITIONERS
2009年
10期
702-705
,共4页
任立敏%穆荣%刘基凤%黄达奇%栗占国
任立敏%穆榮%劉基鳳%黃達奇%慄佔國
임립민%목영%류기봉%황체기%률점국
痛风%数据收集%伴发疾病
痛風%數據收集%伴髮疾病
통풍%수거수집%반발질병
Gout%Data collection%Associated diseases
目的 了解痛风患者伴发疾病情况及目前痛风的诊治现状.方法 采用现况调查方法,对2008年4月至10月就诊于北京大学人民医院风湿科门诊的200例痛风患者的一般资料、伴发疾病、诊断及治疗进行现场调查,并记录近3个月的血脂、血肌酐、血尿酸、尿常规结果,用肾脏病膳食改良试验(MDRD)公式计算肾小球滤过率.结果 痛风患者伴发高血压、肥胖、肾结石、冠心病、脑梗死、糖尿病的分别为54.5%(109/200)、23.2%(42/181)、20.0%(40/200)、12.0%(24/200)、8.0%(16/200)和7.0%(14/200).伴发高甘油三酯血症为53.7%(101/188).63.7%(114/179)的患者有肾功能下降,15.1%(27/179)伴发慢性肾脏病.200例患者中分别有124例(62%)、72例(36%)、12例(6%)和30例(15%)于痛风急性发作期使用非甾体抗炎药、秋水仙碱、糖皮质激素及降血尿酸药物.痛风间歇期,符合较公认降血尿酸治疗指征的患者中69.8%(81/116)接受过降血尿酸治疗,仅8.6%(10/116)血尿酸水平维持在0.06 g/L以下.不符合降血尿酸治疗指征者中73.8%(48/65)也接受了降血尿酸治疗.结论 痛风患者最常见的伴发疾病是高血压、高脂血症及肥胖,其次是肾结石、慢性肾脏病和冠心病等.非甾体抗炎药是痛风急性发作期首选治疗,患者降血尿酸治疗时机与目前国际上较公认的指征不一致,达到治疗目标的比例低.
目的 瞭解痛風患者伴髮疾病情況及目前痛風的診治現狀.方法 採用現況調查方法,對2008年4月至10月就診于北京大學人民醫院風濕科門診的200例痛風患者的一般資料、伴髮疾病、診斷及治療進行現場調查,併記錄近3箇月的血脂、血肌酐、血尿痠、尿常規結果,用腎髒病膳食改良試驗(MDRD)公式計算腎小毬濾過率.結果 痛風患者伴髮高血壓、肥胖、腎結石、冠心病、腦梗死、糖尿病的分彆為54.5%(109/200)、23.2%(42/181)、20.0%(40/200)、12.0%(24/200)、8.0%(16/200)和7.0%(14/200).伴髮高甘油三酯血癥為53.7%(101/188).63.7%(114/179)的患者有腎功能下降,15.1%(27/179)伴髮慢性腎髒病.200例患者中分彆有124例(62%)、72例(36%)、12例(6%)和30例(15%)于痛風急性髮作期使用非甾體抗炎藥、鞦水仙堿、糖皮質激素及降血尿痠藥物.痛風間歇期,符閤較公認降血尿痠治療指徵的患者中69.8%(81/116)接受過降血尿痠治療,僅8.6%(10/116)血尿痠水平維持在0.06 g/L以下.不符閤降血尿痠治療指徵者中73.8%(48/65)也接受瞭降血尿痠治療.結論 痛風患者最常見的伴髮疾病是高血壓、高脂血癥及肥胖,其次是腎結石、慢性腎髒病和冠心病等.非甾體抗炎藥是痛風急性髮作期首選治療,患者降血尿痠治療時機與目前國際上較公認的指徵不一緻,達到治療目標的比例低.
목적 료해통풍환자반발질병정황급목전통풍적진치현상.방법 채용현황조사방법,대2008년4월지10월취진우북경대학인민의원풍습과문진적200례통풍환자적일반자료、반발질병、진단급치료진행현장조사,병기록근3개월적혈지、혈기항、혈뇨산、뇨상규결과,용신장병선식개량시험(MDRD)공식계산신소구려과솔.결과 통풍환자반발고혈압、비반、신결석、관심병、뇌경사、당뇨병적분별위54.5%(109/200)、23.2%(42/181)、20.0%(40/200)、12.0%(24/200)、8.0%(16/200)화7.0%(14/200).반발고감유삼지혈증위53.7%(101/188).63.7%(114/179)적환자유신공능하강,15.1%(27/179)반발만성신장병.200례환자중분별유124례(62%)、72례(36%)、12례(6%)화30례(15%)우통풍급성발작기사용비치체항염약、추수선감、당피질격소급강혈뇨산약물.통풍간헐기,부합교공인강혈뇨산치료지정적환자중69.8%(81/116)접수과강혈뇨산치료,부8.6%(10/116)혈뇨산수평유지재0.06 g/L이하.불부합강혈뇨산치료지정자중73.8%(48/65)야접수료강혈뇨산치료.결론 통풍환자최상견적반발질병시고혈압、고지혈증급비반,기차시신결석、만성신장병화관심병등.비치체항염약시통풍급성발작기수선치료,환자강혈뇨산치료시궤여목전국제상교공인적지정불일치,체도치료목표적비례저.
Objective To investigate prevalence of associated diseases in patients with gout as well as their diagnoses and treatment. Methods Two hundreds out-patients diagnosed with gout from April to October 2008 were investigated at Peking University People's Hospital, and information collected included their general characteristics, associated diseases, diagnoses and treatment, as well as blood lipid profiles, serum creatinine, uric acid, results of routine urine tests and glomerular filtration rate estimated by MDRD formula in the past three months. Results Among patients with gout, prevalence of associated hypertension, obesity, renal calculi, coronary heart disease, cerebral infarction and diabetes were 54.5% (109/200), 23.2% (42/181), 20.0% (40/200), 12.0% (24/200), 8.0% (16/200) and 7.0% (14/200), respectively, and 53.7% (101/188) of them associated with hypertriglyceridemia, 63.7% (114/179) with impaired renal function and 15.1% (27/179) with chronic kidney disease. In acute attack of gout, 124 (62.0%) of them were treated with non-steroidal anti-inflammatory drug (NASID), 72 (36.0%) with colchicines, 12 (6.0%) with corticosteroid and 30 (15.0%) with urate-lowering drugs, respectively, and during its intermittent period, 69. 8% (81/116) of them received urate-lowering therapy with indications generally accepted internationally, but serum level of uric acid could be maintained below 0.06 g/L in only 8.6% (10/116) of them. And 73.8% (48/65) of the patients with no therapy indications also were treated with urate-lowering drugs. Conclusions The most commonly associated diseases in gout patients are hypertension, hyperlipidemia and obesity, followed by renal calculi, chronic kidney disease and coronary heart disease, and so on. At present, oral NSAID is the first choice of drugs for its acute attack. Indications for urate-lowering therapy in this hospital usually are not consistent with those by generally international acceptance, with lower therapeutic effectiveness achieved.